MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$266,044K
Net Income
$24,711K
Net Profit Margin
9.29%
EPS
$1.05
Unit: Thousand (K) dollars
Revenue Breakdown
Sales Of Cortrophin Gel
Sales Of Generic Pharmaceutical ...
Sales Of ILUVIENAnd YUTIQ
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net revenues
266,044
237,462
224,592*
227,813
Cost of sales (excluding depreciation and amortization)
100,158
93,582
90,897*
93,389
Research and development
14,747
10,600
8,406*
12,304
Selling, general, and administrative
91,661
73,655
80,105*
76,656
Depreciation and amortization
19,640
20,919
22,548*
22,632
Contingent consideration fair value adjustment
-622
-182
-11,222*
-14,470
Gain (loss) on disposal of assets
-
-
503*
-295
Restructuring activities
-
-
0*
-
Intangible asset impairment charge
-
-
-1,534*
767
Total operating expenses, net
225,584
198,574
188,695*
191,573
Operating income
40,460
38,888
35,897*
36,240
Unrealized loss (gain) on investment in equity securities
741
5,753
-2,384*
3,140
Interest expense, net
-3,636
-3,769
-4,812*
-4,727
Other (expense) income, net
-468
-651
605*
-853
Loss on extinguishment of debt
-
-
0*
0
Income before income tax expense
37,097
40,221
29,305*
33,800
Income tax expense
12,386
10,729
3,716*
7,183
Net income
24,711
29,492
25,589*
26,617
Dividends on series a convertible preferred stock
0
0
31*
344
Net income available to common shareholders
24,711
29,492
25,558
26,273
Basic EPS
1.09
1.31
1.262
1.19
Diluted EPS
1.05
1.28
1.147
1.13
Basic Average Shares
21,158,000
20,914,000
20,251,000
20,074,000
Diluted Average Shares
21,915,000
21,544,000
22,283,000
21,093,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Sales Of Cortrophin
Gel
$117,126K
Sales Of ILUVIENAnd
YUTIQ
$18,718K
(-16.12%↓ Y/Y)
Total Sales Of Rare
Disease Pharmaceutical...
$135,844K
(30.67%↑ Y/Y)
Sales Of Established
Brand Royalties And...
$17,731K
Sales Of Established
Brands
$11,813K
(-10.47%↓ Y/Y)
Sales Of Generic
Pharmaceutical Products
$99,051K
(9.69%↑ Y/Y)
Sales Of Generic Other
Revenues
$1,605K
Total Sales Of Rare
Disease And Brands
$165,388K
(41.17%↑ Y/Y)
Total Sales Of
Generics And Other
$100,656K
(6.84%↑ Y/Y)
Net revenues
$266,044K
(25.87%↑ Y/Y)
Operating income
$40,460K
(191.25%↑ Y/Y)
Unrealized loss (gain) on
investment in equity...
$741K
(123.19%↑ Y/Y)
Total operating
expenses, net
$225,584K
(14.23%↑ Y/Y)
Contingent consideration
fair value...
-$622K
(-148.71%↓ Y/Y)
Income before income
tax expense
$37,097K
(252.47%↑ Y/Y)
Interest expense, net
-$3,636K
(33.14%↑ Y/Y)
Other (expense)
income, net
-$468K
(-126.91%↓ Y/Y)
Cost of sales
(excluding depreciation...
$100,158K
(34.23%↑ Y/Y)
Selling, general, and
administrative
$91,661K
(12.09%↑ Y/Y)
Depreciation and
amortization
$19,640K
(-15.64%↓ Y/Y)
Research and development
$14,747K
(-10.81%↓ Y/Y)
Net income
$24,711K
(189.05%↑ Y/Y)
Income tax expense
$12,386K
(526.82%↑ Y/Y)
Net income
available to common...
$24,711K
Buy us a coffee
ANI PHARMACEUTICALS INC (ANIP)
ANI PHARMACEUTICALS INC (ANIP)